Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.56 |
| ▸ | AR | P10275 | 5/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984405 | 0.86 | PGR (0.58) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL984515 | 0.85 | CYP3A4 (0.61) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL984513 | 0.85 | CYP3A4 (0.61) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL982096 | 0.85 | CYP3A4 (0.61) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL921539 | 0.82 | PGR (0.60) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL924095 | 0.82 | PGR (0.60) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL986158 | 0.80 | CYP19A1 (0.43) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL982089 | 0.79 | CYP19A1 (0.42) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL13474765 | 0.78 | PGR (0.66) | PGRARCYP3A4ABCB11LMNA | |
| SCHEMBL982238 | 0.77 | PGR (0.50) | PGRARCYP3A4ABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937058-B2 | 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivative, use thereof, and medicament containing the derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-20 | — | — | US | claimed |
| US-20110021472-A1 | 17-HYDROXY-19-NOR-21-CARBOXYLIC ACID-STEROID Y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING THE DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-01-27 | — | — | US | claimed |
| US-8937058-B2 | 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivative, use thereof, and medicament containing the derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20110021472-A1 | 17-HYDROXY-19-NOR-21-CARBOXYLIC ACID-STEROID Y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING THE DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021472-A1 | 17-HYDROXY-19-NOR-21-CARBOXYLIC ACID-STEROID Y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING THE DERIVATIVE | CYP17A1, NR5A1, CYP19A1 | PGR 29/4885AR 39/4885CYP3A4 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.